While a dedicated large-scale cagrilintide-plus-tirzepatide phase 3 trial is still ongoing, early-phase data offers useful signals about how the combination behaves
169,177,178 In a preliminary trial in 17 healthy reproductive-aged women, taking 4,000 mg of an omega-3 fatty acid supplement (providing 1,860 mg eicosapentaenoic acid [EPA] and 1,500 mg docosahexaenoic acid [DHA]) daily for one month led to reductions in levels of FSH, a hormonal marker of diminished ovarian reserve and early menopause, in normal weight, but not obese, participants
On average, patients lost eight kilograms (17.5 lbs) at 50 milligrams, which is nearly twice as much weight loss that we saw with the lowest dose. The new study is in line with other studies, which are pushing for the use of oral GLP-1 receptor agonists as a treatment for obesity
That same pathway, when chronically overactive, is one of the best-documented drivers of cancer growth and spread, to the point that a class of approved cancer drugs exists specifically to block it
